Production of Oral Vaccines Based on Virus-Like Particles Pseudotyped with Protozoan-Surface Proteins.
Giardia lamblia
Oral vaccines
Protozoan-surface proteins
Variant-specific surface proteins (VSPs)
Virus-like particles
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
16
12
2021
pubmed:
17
12
2021
medline:
20
1
2022
Statut:
ppublish
Résumé
Giardia lamblia is the only known parasite that can inhabit the harsh upper gastrointestinal tract, where most of the digestive proteases are secreted. Intestinal and free-living protozoa express surface proteins containing an extraordinarily high percentage of cysteine. These cysteine-rich variant-specific surface proteins (VSPs) form a dense coat on the entire surface of Giardia trophozoites, that coat protects the parasite inside the host intestine. VSPs not only are resistant to proteolytic digestion, extreme pH and temperatures, but also stimulate host immune responses. These properties can be used to protect as well as to increase the immunogenicity of vaccine antigens for oral administration. The incorporation of VSPs onto virus-like particles bearing viral antigens allows oral administration of these vaccines, protecting the antigens from degradation and generating robust and protective immune responses. In this chapter we describe the development of this versatile vaccine platform for the generation of safe, stable, and efficient oral vaccines, including their production and validation, as well as the characterization of immune response to oral immunization.
Identifiants
pubmed: 34914065
doi: 10.1007/978-1-0716-1884-4_26
doi:
Substances chimiques
Antigens, Protozoan
0
Membrane Proteins
0
Protozoan Proteins
0
Protozoan Vaccines
0
Vaccines
0
Cysteine
K848JZ4886
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
503-537Informations de copyright
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Vela Ramirez JE, Sharpe LA, Peppas NA (2017) Current state and challenges in developing oral vaccines. Adv Drug Deliv Rev 114:116–131. https://doi.org/10.1016/j.addr.2017.04.008
doi: 10.1016/j.addr.2017.04.008
pubmed: 28438674
pmcid: 6132247
Rupil LL, del Serradell MC, Luján HD (2019) Using protozoan surface proteins for effective oral vaccination. Trends Parasitol 36(1):7–10. https://doi.org/10.1016/j.pt.2019.07.004
doi: 10.1016/j.pt.2019.07.004
pubmed: 31362858
Prucca CG, Slavin I, Quiroga R et al (2008) Antigenic variation in Giardia lamblia is regulated by RNA interference. Nature 456:750–754. https://doi.org/10.1038/nature07585
doi: 10.1038/nature07585
pubmed: 19079052
Serradell MC, Rupil LL, Martino RA et al (2019) Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins. Nat Commun 10:361. https://doi.org/10.1038/s41467-018-08265-9
doi: 10.1038/s41467-018-08265-9
pubmed: 30664644
pmcid: 6341118
Rivero FD, Saura A, Prucca CG et al (2010) Disruption of antigenic variation is crucial for effective parasite vaccine. Nat Med 16:551–557. https://doi.org/10.1038/nm.2141
doi: 10.1038/nm.2141
pubmed: 20418884
Serradell MC, Saura A, Rupil LL et al (2016) Vaccination of domestic animals with a novel oral vaccine prevents giardia infections, alleviates signs of giardiasis and reduces transmission to humans. NPJ Vaccines 1:16018. https://doi.org/10.1038/npjvaccines.2016.18
doi: 10.1038/npjvaccines.2016.18
pubmed: 29263857
pmcid: 5707882
Tan M, Jiang X (2017) Recent advancements in combination subunit vaccine development. Hum Vaccin Immunother 13:180–185. https://doi.org/10.1080/21645515.2016.1229719
doi: 10.1080/21645515.2016.1229719
pubmed: 27649319
Millet JK, Tang T, Nathan L et al (2019) Production of Pseudotyped particles to study highly pathogenic coronaviruses in a biosafety level 2 setting. J Vis Exp:59010. https://doi.org/10.3791/59010
Szécsi J, Boson B, Johnsson P et al (2006) Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol J 3:70. https://doi.org/10.1186/1743-422X-3-70
doi: 10.1186/1743-422X-3-70
pubmed: 16948862
pmcid: 1569823
Garrone P, Fluckiger A-C, Mangeot PE et al (2011) A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 3:94ra71. https://doi.org/10.1126/scitranslmed.3002330
doi: 10.1126/scitranslmed.3002330
pubmed: 21813755
Yu Z, Beer C, Koester M, Wirth M (2006) Caveolin-1 interacts with the gag precursor of murine leukaemia virus and modulates virus production. Virol J 3:73. https://doi.org/10.1186/1743-422X-3-73
doi: 10.1186/1743-422X-3-73
pubmed: 16956408
pmcid: 1570462
Kurg R, Reinsalu O, Jagur S et al (2016) Biochemical and proteomic characterization of retrovirus gag based microparticles carrying melanoma antigens. Sci Rep 6:29425. https://doi.org/10.1038/srep29425
doi: 10.1038/srep29425
pubmed: 27403717
pmcid: 4941533
O’Gorman S, Fox D, Wahl G (1991) Recombinase-mediated gene activation and site-specific integration in mammalian cells. Science 251:1351–1355. https://doi.org/10.1126/science.1900642
doi: 10.1126/science.1900642
pubmed: 1900642
Stuchbury G, Münch G (2010) Optimizing the generation of stable neuronal cell lines via pre-transfection restriction enzyme digestion of plasmid DNA. Cytotechnology 62:189–194. https://doi.org/10.1007/s10616-010-9273-1
doi: 10.1007/s10616-010-9273-1
pubmed: 20424915
pmcid: 2932902
Hnasko TS, Hnasko RM (2015) The Western blot. Methods Mol Biol 1318:87–96. https://doi.org/10.1007/978-1-4939-2742-5_9
doi: 10.1007/978-1-4939-2742-5_9
pubmed: 26160567
Killian ML (2020) Hemagglutination assay for influenza virus. Methods Mol Biol 2123:3–10. https://doi.org/10.1007/978-1-0716-0346-8_1
doi: 10.1007/978-1-0716-0346-8_1
pubmed: 32170676
Griffiths D, Carnell-Morris P, Wright M (2020) Nanoparticle tracking analysis for multiparameter characterization and counting of nanoparticle suspensions. In: Ferrari E, Soloviev M (eds) Nanoparticles in biology and medicine. Springer US, New York, NY, pp 289–303
doi: 10.1007/978-1-0716-0319-2_22
Gonda MA (1998) Electron microscopy, immunological applications. In: Encyclopedia of immunology. Elsevier, Amsterdam, pp 790–795
doi: 10.1006/rwei.1999.0209
Zimmermann P, Curtis N (2019) Factors that influence the immune response to vaccination. Clin Microbiol Rev 32:e00084. https://doi.org/10.1128/CMR.00084-18
doi: 10.1128/CMR.00084-18
pubmed: 30867162
pmcid: 6431125
Liu MA (1997) The immunologist’s grail: vaccines that generate cellular immunity. Proc Natl Acad Sci 94:10496–10498. https://doi.org/10.1073/pnas.94.20.10496
doi: 10.1073/pnas.94.20.10496
pubmed: 9380667
pmcid: 33772
Sakamoto S, Putalun W, Vimolmangkang S et al (2018) Enzyme-linked immunosorbent assay for the quantitative/qualitative analysis of plant secondary metabolites. J Nat Med 72:32–42. https://doi.org/10.1007/s11418-017-1144-z
doi: 10.1007/s11418-017-1144-z
pubmed: 29164507
World Health Organization (WHO) WHO manual on animal influenza diagnosis and surveillance
Kaiko GE, Horvat JC, Beagley KW, Hansbro PM (2008) Immunological decision-making: how does the immune system decide to mount a helper T-cell response? Immunology 123:326–338. https://doi.org/10.1111/j.1365-2567.2007.02719.x
doi: 10.1111/j.1365-2567.2007.02719.x
pubmed: 17983439
pmcid: 2433332
Ji N, Forsthuber TG (2016) ELISPOT techniques. Methods Mol Biol 1304:63–71. https://doi.org/10.1007/7651_2014_111
doi: 10.1007/7651_2014_111
pubmed: 25117217
Kim GG, Donnenberg VS, Donnenberg AD et al (2007) A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay. J Immunol Methods 325:51–66. https://doi.org/10.1016/j.jim.2007.05.013
doi: 10.1016/j.jim.2007.05.013
pubmed: 17617419
pmcid: 2040258
Hillaire MLB, Osterhaus ADME, Rimmelzwaan GF (2011) Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J Biomed Biotechnol 2011:1–12. https://doi.org/10.1155/2011/939860
doi: 10.1155/2011/939860
Noto A, Ngauv P, Trautmann L (2013) Cell-based flow cytometry assay to measure cytotoxic activity. J Vis Exp:e51105. https://doi.org/10.3791/51105
Marzo AL, Lake RA, Lo D et al (1999) Tumor antigens are constitutively presented in the draining lymph nodes. J Immunol 162:5838–5845
pubmed: 10229818
Gerdts V, Wilson HL, Meurens F et al (2015) Large animal models for vaccine development and testing. ILAR J 56:53–62. https://doi.org/10.1093/ilar/ilv009
doi: 10.1093/ilar/ilv009
pubmed: 25991698
Bouvier NM, Lowen AC (2010) Animal models for influenza virus pathogenesis and transmission. Viruses 2:1530–1563. https://doi.org/10.3390/v20801530
doi: 10.3390/v20801530
pubmed: 21442033
pmcid: 3063653
Cottey R, Rowe CA, Bender BS (2001) Influenza Virus. Curr Protoc Immunol 42:19.11.1–19.11.32. https://doi.org/10.1002/0471142735.im1911s42
doi: 10.1002/0471142735.im1911s42
Hedrich H, Gillian B (2004) The laboratory mouse. Elsevier, Amsterdam
Van Hoecke L, Job ER, Saelens X, Roose K (2017) Bronchoalveolar lavage of murine lungs to analyze inflammatory cell infiltration. J Vis Exp (123):55398. https://doi.org/10.3791/55398
Wonderlich J, Shearer G, Livingstone A et al (2018) Induction and measurement of cytotoxic T lymphocyte activity. Curr Protoc Immunol 120:3.11.1–3.11.29. https://doi.org/10.1002/cpim.38
doi: 10.1002/cpim.38
Quah BJC, Warren HS, Parish CR (2007) Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc 2:2049–2056. https://doi.org/10.1038/nprot.2007.296
doi: 10.1038/nprot.2007.296
pubmed: 17853860
Riss T, Niles A, Moravec R et al (2004) Cytotoxicity assays: in vitro methods to measure dead cells. In: Sittampalam GS, Grossman A, Brimacombe K et al (eds) Assay guidance manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda (MD)